- Second primary malignancies after commercial CAR T|cell therapy🔍
- Second Primary Malignancies after CAR T|Cell Therapy🔍
- Characterization of second primary malignancies post CAR T|cell ...🔍
- Data mining for second malignancies after CAR|T🔍
- T cell lymphoma and secondary primary malignancy risk after ...🔍
- T|cell Malignancies Represent Small Fraction of the Reported ...🔍
- Study shows CAR T|cell therapy's risk of second primary ...🔍
- Secondary Cancers after Chimeric Antigen Receptor T|Cell Therapy🔍
Second primary malignancies after commercial CAR T|cell therapy
Second primary malignancies after commercial CAR T-cell therapy
Second primary malignancies were reported in 536 of 12 394 (4.3%) adverse event reports following chimeric antigen receptor T-cell therapies ...
Second Primary Malignancies after CAR T-Cell Therapy
Purpose: Chimeric antigen receptor (CAR) T-cell therapy is a potent immunotherapy for hematologic malignancies, but patients can develop long- ...
Characterization of second primary malignancies post CAR T-cell ...
SPMs post CAR T-cell therapy include HMs and solid tumors. T-cell lymphoma and myelodysplastic syndromes were consistently identified as ...
Second Primary Malignancies after CAR T-Cell Therapy - PubMed
Purpose: Chimeric antigen receptor (CAR) T-cell therapy is a potent immunotherapy for hematologic malignancies, but patients can develop long- ...
Data mining for second malignancies after CAR-T - ASH Publications
They found that second primary malignancies were reported in 536 of 12 394 (4.3%) adverse events after CAR-T therapies in FAERS.
T cell lymphoma and secondary primary malignancy risk after ...
To assess the overall risk of secondary primary malignancy after commercial CAR T (CD19, BCMA), we analyzed 449 patients treated at the ...
Second primary malignancies after commercial CAR T-cell therapy
Second primary malignancies were reported in 536 of 12 394 (4.3%) adverse event reports following chimeric antigen receptor T-cell therapies.
T-cell Malignancies Represent Small Fraction of the Reported ...
“At this point, the risk of secondary cancers after CAR T-cell therapy cannot be definitively attributed to the CAR T cells as all of these ...
Study shows CAR T-cell therapy's risk of second primary ...
The frequency of second primary malignancies (SPMs) arising in cancer survivors following treatment with CAR T-cell therapy was ...
Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy
Among the 14 cases for which adequate data are currently available, the cancers have manifested within 2 years after administration of CAR T cells (range, 1 to ...
The Risk of Secondary Cancers After CAR T-cell Therapy | Blog
While individual studies suggested that the risk of secondary T-cell cancers after CAR T therapy was relatively low, each had its own ...
Rarity & Risk of Secondary Hematologic Neoplasms after CAR T-cell ...
Collectively, Lorenc and colleagues present an important additional analysis of second malignancies after CAR T-cell therapy through study of a large cohort.
Evaluating Secondary Primary Malignancy Risk After CAR T-cell ...
The FDA Adverse Event Reporting System (FEARS) reported secondary primary malignancies in 4.3% of patients who received CAR T-cell therapies.
The Current Landscape of Secondary Malignancies after CAR T ...
The exact causes driving the development of secondary malignancies after CAR T-cell therapies are unclear. Regarding the T-cell malignancies, none of the 22 ...
Following FDA's Call for CAR T Boxed Warnings, Questions About ...
While the risk of secondary malignancies has been a class warning for CAR T-cell therapies since the first approval of tisagenleleucel (Kymriah; ...
Effectiveness of CAR-T treatment toward the potential risk of second ...
Pre-existing mutations in patients receiving CAR-T cell therapies can result in secondary malignancies in some cases (63). A recently published ...
Subsequent Malignancies After CD19-Targeted Chimeric Antigen ...
The cumulative incidence of subsequent malignancies after CAR T cells was 14%. •. Solid tumors were seen in 6.1% of patients after CAR T cell therapy. •.
Registry Data Inconclusive on Risk of Secondary Primary ...
SPMs were reported in 536 of the 12,394 AE reports following CAR T-cell therapy made to FAERS, with myeloid and T-cell neoplasms more frequently ...
The risk of secondary primary malignancy after CAR-T therapy
Marco Ruella, MD, University of Pennsylvania, Philadelphia, PA, comments on the risk of secondary primary malignancy in patients receiving ...
Secondary Cancers After CAR T-Cell Therapy - The ASCO Post
They found that the rate of second primary malignancies compared to patients receiving previous standard-of-care therapy was not statistically ...